Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Drug Repositioning
share announcement

Drug Repositioning

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 October 2013) | Viewed by 15953

Special Issue Editor

Prof. Dr. Louis M. Mansky

E-Mail Website
Guest Editor
Institute for Molecular Virology, Division of Basic Sciences, University of Minnesota, Minneapolis, MN, USA
Interests: human retroviruses; virus assembly; reverse transcription; retroviral diversity and evolution; antiretroviral
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A current way to decrease the cost and expedite the development of novel drugs is to use the strategy of drug repositioning (drug repurposing). This strategy involves the use of drugs that are clinically approved for one condition to treat a different condition. Drug repositioning can expedite drug development by making use of drugs whose toxicity and pharmacokinetic profiles have already been extensively characterized. Drug repositioning has been successfully used for the treatment of conditions such as cancer, obesity, and osteoporosis, as well as others. Much promise exists for the successful repositioning of other drugs.

Prof. Dr. Louis M. Mansky
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug repositioning
  • drug repurposing
  • indications discovery
  • drug re-profiling
  • therapeutic switching
  • drug re-tasking
  • indication expansion
  • lifecycle extension

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

845 KiB  
Article
Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways
by Ramesh B. Batchu, Oksana V. Gruzdyn, Christopher S. Bryant, Aamer M. Qazi, Sanjeev Kumar, Sreedhar Chamala, Shu T. Kung, Ramana S. Sanka, Udaya S. Puttagunta, Donald W. Weaver and Scott A. Gruber
Pharmaceuticals 2014, 7(1), 46-57; https://doi.org/10.3390/ph7010046 - 09 Jan 2014
Cited by 39 | Viewed by 7469
Abstract
Recent observations suggest a lower incidence of malignancies in patients infected with HIV during treatment with Highly Active Anti-Retroviral Therapy (HAART) utilizing protease inhibitors. We investigated the effects of ritonavir, a FDA approved HIV protease inhibitor, on proliferation of pancreatic ductal adeno-carcinoma (PDAC) [...] Read more.
Recent observations suggest a lower incidence of malignancies in patients infected with HIV during treatment with Highly Active Anti-Retroviral Therapy (HAART) utilizing protease inhibitors. We investigated the effects of ritonavir, a FDA approved HIV protease inhibitor, on proliferation of pancreatic ductal adeno-carcinoma (PDAC) cell lines. Human PDAC cell lines BxPC-3, MIA PaCa-2, and PANC-1 were propagated under standard conditions and treated with serial dilutions of ritonavir. Ritonavir inhibited cell growth in a dose-dependent manner as well as activated the intrinsic apoptotic pathway in human pancreatic ductal adenocarcinoma (PDAC) cell lines. We observed down-modulation of cell-cycle promoting and up-regulation of cell-cycle inhibitory genes; enhanced interaction of retinoblastoma protein (RB) with E2F-1 transcription factor; inhibition of phosphorylation of RB, resulting in sequestration of E2F-1 and subsequent down-regulation of S phase genes; decreased interaction of E2F-1 with its consensus binding sites; inhibition of cell motility and invasiveness; and inhibition of the AKT pathway. Our results demonstrate a potential use of ritonavir as part of combination chemotherapy for PDAC. Since ritonavir is FDA approved for HIV, drug repositioning for PDAC would limit the costs and reduce risks. Full article
(This article belongs to the Special Issue Drug Repositioning)
►▼ Show Figures

Figure 1

Review

Jump to: Research

145 KiB  
Review
Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
by Anne Corbett, Gareth Williams and Clive Ballard
Pharmaceuticals 2013, 6(10), 1304-1321; https://doi.org/10.3390/ph6101304 - 11 Oct 2013
Cited by 40 | Viewed by 7828
Abstract
Alzheimer’s Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There [...] Read more.
Alzheimer’s Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery. Full article
(This article belongs to the Special Issue Drug Repositioning)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop